ICAL TRIAL TO ROLL OUT SOON On September 1, the DCGI gave permission to the co

 

approval based on the interim data of phase 1 and phase 2 clinical trials — similar to Bharat Biotech’s Covaxin. The results of phase 3 trials are expected to take around seven more months.

Corbevax, the third made-in India jab against coronavirus, is an recombinant protein sub-unit vaccine, which is made by using a specific part of virus (SARS-CoV-2) — the spike protein on the virus’s surface. The other two indeginous vaccines are Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCoV-D.

According to two senior government officials, the company has been asked to submit the phase 1 and phase 2 trial data after completing the interim analysis of its efficacy. “The company is engaged in the corroboration of data and interim analysis. As soon as they finish the due process, they will submit the data to the subject expert committee (SEC) and Drug Controller General of India (DCGI),” said a government official privy to the development. “We are hoping to receive the data by the end of September or by early October.”

News18 reached out to Biological E through email for an official comment on the matter, 



Latest News & Tips | Simple explanation of news

far, has proven to be safe. “We need to understand its efficacy. While the platform used for manufacturing the vaccine is highly effective and has been used in multiple vaccines since the last many decades, the due process will be followed before it gets the final approval.”

He further added that if approved on the basis of phase 2 clinical data, the same rules applied to Covaxin (earlier) will be followed. “Covaxin was given conditional approval till the time their phase 3 trials were concluded. The follow up (among vaccine recipients) was more stringent and frequent. However, the final decision (on Corbevax) will be taken after deliberations by the SEC and DCGI,” the second official said, adding that “the company has already started producing a stockpile. The immediate roll-out is possible as soon as it gets approval”.

The central government has placed an advance order for 30 crore doses of Corbevax. It is a two-dose vaccine with an interval of 28 days.

THIRD PHASE OF CLINICAL TRIAL TO ROLL OUT SOON

On September 1, the DCGI gave permission to the company to conduct phase 2/3 clinical trials of Corbevax on children between five-18 years with certain conditions.

Among adults (18-80 years), the preparations of phase 3 study are in full swing at 




Comments

Post a Comment

Popular posts from this blog

gious sites not only for Mumbaikars, but also for

  most popular religious sites not only for Mumbaikars, but also for millions of tourists visiting the city from various parts of the country and world. The morning Kakad Aarti takes place every Wednesday to Monday from 5.30 am to 6.00 am and evening aarti from 7:30 pm to 8 pm. On Tuesday, the Shree darshan starts at 3:15 am to 4:45 am, while the Kakad Aarti is held from 5 am to 5.30 am. The evening aarti is held from 7:30 pm to 8 pm. ‘NO SARVAJANIK (PUBLIC) GANPATI IDOLS IMMERSED’ According to the civic body, no “ 1   2   …   5 Next Page  → sarvajanik" (public) Ganpati idols were immersed till Tuesday afternoon and no untoward incidents have been reported from any part of the city. As many as 41 domestic idols were immersed in artificial ponds built for the purpose, the official said, adding that six idols of goddess Gauri were also immersed on the occasion. The 10-day Ganesh Chaturthi festival, which usually sees millions crowding the city streets, is being celebrated in a low-k
Read more

munisation Programme from this month,

  ndia (SII) will start supplying Inactivated Polio Vaccine (IPV) to the Union government for the Universal Immunisation Programme from this month, becoming the first indigenous company to do so, official sources said on Tuesday. The Union Health Ministry has recently placed a purchase order with SII for 54 lakh doses of IPV vaccine. So far, the government was dependent on Sanofi, a foreign pharmaceutical company for supplying IPV to the universal immunisation programme. “I wish to inform you that our firm, Serum Insti Top Websites in the US by Traffic [July 2021] websites   /   1 Com tute of India has become the first Indian manufacturer to supply Inactivated Poliomyelitis Vaccine (IPV) to MoHFW which will protect children of our country from Poliomyelitis disease," Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII communicated to the Health Ministry recently. The IPV of SII is World Health Organisation pre-qualified for supplies to various co
Read more